Form 8-K · Current Report · Filed 2026-05-04
Gilead Sciences Elects New Board Members and Approves Key Proposals at 2026 Annual Meeting
Gilead Sciences, Inc. held its 2026 annual meeting of stockholders on April 30, 2026. The meeting saw the election of nine new directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm, and the approval of the amended Gilead Sciences, Inc. 2022 Equity Incentive Plan. Stockholder proposals regarding an independent Board Chair policy, the impact of extended patent exclusivities on patient access, and the risks of ESG and DEI executive compensation metrics were not approved.
- Filer
- Gilead Sciences Inc. GILD · NASDAQ
- Filed
- Accession
- 0000882095-26-000008
- CIK
- 0000882095
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$131.65
Next session
+1.4%
Since filing
-1.1%
Latest close
$130.21
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from GILD reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, GILD insiders reported 29 Form 4 transactions — net selling of $6.0M.
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Never miss another GILD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.